The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
|Videos|May 26, 2017
Dr. Strosberg on Understanding the Current Field of Neuroendocrine Tumors
Author(s)Jonathan R. Strosberg, MD
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).
Advertisement
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).
After years of everolimus (Afinitor) and metastin analogs, the field is in a stage of expansion, says Strosberg. Agents such as telotristat ethyl (Xermelo) are signifying that new drugs—although niche—are signaling advancement in the treatment of NETs.
Advertisement
Related to this article
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5